person · Reporting owner

Kayyem Jon Faiz

Disclosed activity across 4 companies

Tapewire entity: 41263
SEC CIK: 0001366268

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BIODESIX INCBDSX · Entity 6053	Director	January 02, 2026	January 06, 2026
GenMark Diagnostics, Inc.GNMK · Entity 140086	SVP, Research & Development	February 02, 2018	February 06, 2018
Inhibrx Biosciences, Inc.INBX · Entity 4576	Director	September 23, 2026	September 23, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIODESIX INC

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	5,443	Reported balance After 2026-01-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-02 · Grant · Acquired 5,443 · Balance 5,443 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.46 · Expires 2036-01-01	Direct	6,354	Reported balance After 2026-01-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-01-02 · Grant · Acquired 6,354 · Balance 6,354 F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").

F2: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.

F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.

GenMark Diagnostics, Inc.

Report date February 02, 2018 · Filed February 06, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	197,622	Reported balance After 2018-02-02 transaction · row 1 1 source row Row 1 · 2018-02-02 · Sale · Disposed 148 · Balance 197,622 F1: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units.
Common StockSEC Table I · non-derivative	IndirectHI Charitable Remainder Uni Trust	55,901	Reported balance Holding disclosure · report date 2018-02-02 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 55,901 F2: The reporting person transferred 5,750 shares of the Issuer's common stock from the HI Charitable Remainder Trust to The Jon Faiz Kayyem and Paige N. Gates Family Trust. F3: Dr. Kayyem is the trustee of the HI Charitable Remainder Uni Trust, trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust, dated April 1, 2000 and the President of In-Motion LLC, the general partner of IFIN LP. Dr. Kayyem disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
Common StockSEC Table I · non-derivative	IndirectThe Jon Faiz Kayyem and Paige N. Gates Family Trust, dated April 1, 2000	88,684	Reported balance Holding disclosure · report date 2018-02-02 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 88,684 F2: The reporting person transferred 5,750 shares of the Issuer's common stock from the HI Charitable Remainder Trust to The Jon Faiz Kayyem and Paige N. Gates Family Trust. F3: Dr. Kayyem is the trustee of the HI Charitable Remainder Uni Trust, trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust, dated April 1, 2000 and the President of In-Motion LLC, the general partner of IFIN LP. Dr. Kayyem disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
Common StockSEC Table I · non-derivative	IndirectIFIN LP	569,308	Reported balance Holding disclosure · report date 2018-02-02 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 569,308 F3: Dr. Kayyem is the trustee of the HI Charitable Remainder Uni Trust, trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust, dated April 1, 2000 and the President of In-Motion LLC, the general partner of IFIN LP. Dr. Kayyem disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units.

F2: The reporting person transferred 5,750 shares of the Issuer's common stock from the HI Charitable Remainder Trust to The Jon Faiz Kayyem and Paige N. Gates Family Trust.

F3: Dr. Kayyem is the trustee of the HI Charitable Remainder Uni Trust, trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust, dated April 1, 2000 and the President of In-Motion LLC, the general partner of IFIN LP. Dr. Kayyem disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.

Inhibrx Biosciences, Inc.

Report date September 23, 2026 · Filed September 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy The Jon F. Kayyem and Paige Gates-Kayyem Family Trust	434,360	Reported balance After 2026-09-23 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-09-23 · Purchase · Acquired 5,000 · Balance 434,360 F1: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
Common StockSEC Table I · non-derivative	IndirectBy Jon Faiz Kayyem Revocable Trust	250,000	Reported balance Holding disclosure · report date 2026-09-23 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 250,000 F2: These securities are directly owned by the Jon Faiz Kayyem Revocable Trust, of which Jon Faiz Kayyem is the trustee.
Common StockSEC Table I · non-derivative	IndirectBy Paige Gates-Kayyem Revocable Trust	250,000	Reported balance Holding disclosure · report date 2026-09-23 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 250,000 F3: These securities are directly owned by the Paige-Gates Kayyem Revocable Trust, of which Jon Faiz Kayyem's spouse is the trustee.
Common StockSEC Table I · non-derivative	IndirectBy Child A	69,843	Reported balance Holding disclosure · report date 2026-09-23 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 69,843 F4: These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
Common StockSEC Table I · non-derivative	IndirectBy Child B	69,843	Reported balance Holding disclosure · report date 2026-09-23 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 69,843 F5: These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.

F2: These securities are directly owned by the Jon Faiz Kayyem Revocable Trust, of which Jon Faiz Kayyem is the trustee.

F3: These securities are directly owned by the Paige-Gates Kayyem Revocable Trust, of which Jon Faiz Kayyem's spouse is the trustee.

F4: These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.

F5: These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Inhibrx, Inc.

Report date May 30, 2024 · Filed May 30, 2024

Section 16 reporting ended · disclosed 2024-05-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy The Jon F. Kayyem and Paige Gates-Kayyem Family Trust	Reported balance After 2024-05-30 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2024-05-30 · Disposition to issuer · Disposed 3,224,301 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company. F3: These securities were directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
Common StockSEC Table I · non-derivative	IndirectBy Child A	Reported balance After 2024-05-30 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2024-05-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company. F4: These securities were held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
Common StockSEC Table I · non-derivative	IndirectBy Child B	Reported balance After 2024-05-30 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2024-05-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company. F5: These securities were held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.52 · Expires 2028-11-26	Direct	Reported balance After 2024-05-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-05-30 · Disposition to issuer · Disposed 17,259 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F8: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock options immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F6: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on November 26, 2019, with the balance having vested and have become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.03 · Expires 2033-05-25	Direct	Reported balance After 2024-05-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-05-30 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F8: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock options immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F7: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.57 · Expires 2032-05-25	Direct	Reported balance After 2024-05-30 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-05-30 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F8: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock options immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F9: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.78 · Expires 2031-06-07	Direct	Reported balance After 2024-05-30 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-05-30 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F8: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock options immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F10: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on June 7, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").

F2: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company.

F3: These securities were directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.

F4: These securities were held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.

F5: These securities were held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.

F6: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on November 26, 2019, with the balance having vested and have become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

F7: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

F8: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock options immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option.

F9: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

F10: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on June 7, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 23, 2026 Filed Sep 23, 2026 20:59 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	PurchaseCommon Stock	5,000	$100.00	$500,000.00	Disclosure SEC source: 0001366268-26-000011 · wk-form4_1790197155.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 434,360 F1 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
September 16, 2026 Filed Sep 17, 2026 21:46 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	PurchaseCommon Stock	5,000	$100.00	$500,000.00	Disclosure SEC source: 0001366268-26-000006 · wk-form4_1789681608.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 429,360 F1 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
September 08, 2026 Filed Sep 8, 2026 21:23 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	PurchaseCommon Stock	5,000	$113.52	$567,580.00	Disclosure SEC source: 0001366268-26-000004 · wk-form4_1788902607.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 424,360 F1 · price: The shares were purchased in multiple transactions at prices ranging from $113.30 to $113.55 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
June 03, 2026 Filed Sep 18, 2026 20:20 UTC Amendment	Inhibrx Biosciences, Inc. INBX · Entity 4576	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $95.22	$0.00	Disclosure SEC source: 0001366268-26-000009 · wk-form4a_1789762826.xml · derivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-06-03 F1 · derivative.exercise_date: This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date. Read SEC document
June 03, 2026 Filed Jun 4, 2026 21:29 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $95.22	$0.00	Disclosure SEC source: 0001366268-26-000002 · wk-form4_1780608544.xml · derivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-06-03 F1 · derivative.exercise_date: This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date. Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:25 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to Buy) · Derivative	6,354	$0.00 Strike: $6.46	$0.00	Disclosure SEC source: 0000905148-26-000069 · form4.xml · derivative · entry 2 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,354 Underlying: Common Stock · 6,354 shares Expires 2036-01-01 F4 · derivative.exercise_date: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer. Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:25 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	5,443	$0.00	$0.00	Disclosure SEC source: 0000905148-26-000069 · form4.xml · derivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,443 Underlying: Common Stock · 5,443 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2 · derivative.exercise_date: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. Read SEC document
May 28, 2025 Filed May 29, 2025 20:27 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $12.91	$0.00	Disclosure SEC source: 0002007919-25-000068 · wk-form4_1748550471.xml · derivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-05-28 F1 · derivative.exercise_date: This stock option will be fully exercisable on May 28, 2026, subject to the reporting person's continued service through such date. Read SEC document
May 20, 2025 Filed May 22, 2025 20:14 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to Buy) · Derivative	42,010	$0.00 Strike: $0.27	$0.00	Disclosure SEC source: 0000905148-25-001893 · form4.xml · derivative · entry 2 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,010 Underlying: Common Stock · 42,010 shares Expires 2035-05-19 F4 · derivative.exercise_date: This option will vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer. Read SEC document
May 20, 2025 Filed May 22, 2025 20:14 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	68,621	$0.00	$0.00	Disclosure SEC source: 0000905148-25-001893 · form4.xml · derivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,621 Underlying: Common Stock · 68,621 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2 · derivative.exercise_date: These RSUs will vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs will vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. Read SEC document
March 27, 2025 Filed Mar 28, 2025 21:37 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	GiftCommon Stock	90,000	$0.00	$0.00	Disclosure SEC source: 0002007919-25-000025 · wk-form4_1743197832.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 419,360 F1 · kind: This transaction involved a gift of 90,000 shares of Common Stock by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to the reporting person's adult children not residing in the reporting person's household, and to which the reporting person does not have a beneficial interest. F2 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
December 16, 2024 Filed Dec 17, 2024 21:29 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	GiftCommon Stock	250,000	$0.00	$0.00	Disclosure SEC source: 0002007919-24-000068 · wk-form4_1734470990.xml · nonDerivative · entry 3 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Paige Gates-Kayyem Revocable Trust Disclosed balance after: 250,000 F1 · kind: Reflects the transfer for no consideration of shares of Common Stock from The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to the Jon Faiz Kayyem Revocable Trust and the Paige-Gates Kayyem Revocable Trust. F4 · ownership.nature: These securities are directly owned by the Paige-Gates Kayyem Revocable Trust, of which Jon Faiz Kayyem's spouse is the trustee. Read SEC document
December 16, 2024 Filed Dec 17, 2024 21:29 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	GiftCommon Stock	250,000	$0.00	$0.00	Disclosure SEC source: 0002007919-24-000068 · wk-form4_1734470990.xml · nonDerivative · entry 2 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Jon Faiz Kayyem Revocable Trust Disclosed balance after: 250,000 F1 · kind: Reflects the transfer for no consideration of shares of Common Stock from The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to the Jon Faiz Kayyem Revocable Trust and the Paige-Gates Kayyem Revocable Trust. F3 · ownership.nature: These securities are directly owned by the Jon Faiz Kayyem Revocable Trust, of which Jon Faiz Kayyem is the trustee. Read SEC document
December 16, 2024 Filed Dec 17, 2024 21:29 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	GiftCommon Stock	500,000	$0.00	$0.00	Disclosure SEC source: 0002007919-24-000068 · wk-form4_1734470990.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 509,360 F1 · kind: Reflects the transfer for no consideration of shares of Common Stock from The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to the Jon Faiz Kayyem Revocable Trust and the Paige-Gates Kayyem Revocable Trust. F2 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
December 06, 2024 Filed Dec 6, 2024 21:51 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	GiftCommon Stock	52,000	$0.00	$0.00	Disclosure SEC source: 0002007919-24-000066 · wk-form4_1733521865.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 1,009,360 F1 · kind: This transaction involved a gift of 52,000 shares of Common Stock by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to the reporting person's adult children not residing in the reporting person's household, and to which the reporting person does not have a beneficial interest. F2 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
November 20, 2024 Filed Nov 22, 2024 21:03 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	PurchaseCommon Stock	18,750	$14.19	$266,101.88	Disclosure SEC source: 0002007919-24-000064 · wk-form4_1732309427.xml · nonDerivative · entry 4 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Child B Disclosed balance after: 69,843 F4 · balance_after: The shares were purchased in multiple transactions at prices ranging from $13.93 to $14.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
November 20, 2024 Filed Nov 22, 2024 21:03 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	PurchaseCommon Stock	18,750	$14.19	$266,101.88	Disclosure SEC source: 0002007919-24-000064 · wk-form4_1732309427.xml · nonDerivative · entry 3 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Child A Disclosed balance after: 69,843 F4 · balance_after: The shares were purchased in multiple transactions at prices ranging from $13.93 to $14.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
November 19, 2024 Filed Nov 22, 2024 21:03 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	PurchaseCommon Stock	34,843	$14.23	$495,707.88	Disclosure SEC source: 0002007919-24-000064 · wk-form4_1732309427.xml · nonDerivative · entry 2 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Child B Disclosed balance after: 51,093 F1 · balance_after: The shares were purchased in multiple transactions at prices ranging from $14.09 to $14.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
November 19, 2024 Filed Nov 22, 2024 21:03 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	PurchaseCommon Stock	34,843	$14.23	$495,707.88	Disclosure SEC source: 0002007919-24-000064 · wk-form4_1732309427.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Child A Disclosed balance after: 51,093 F1 · balance_after: The shares were purchased in multiple transactions at prices ranging from $14.09 to $14.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
June 24, 2024 Filed Jun 24, 2024 21:27 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	GiftCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0002007919-24-000024 · wk-form4_1719264429.xml · nonDerivative · entry 3 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Child B Disclosed balance after: 16,250 F4 · kind: This transaction involved a gift of 10,000 shares of Common Stock by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
June 24, 2024 Filed Jun 24, 2024 21:27 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	GiftCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0002007919-24-000024 · wk-form4_1719264429.xml · nonDerivative · entry 2 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Child A Disclosed balance after: 16,250 F3 · kind: This transaction involved a gift of 10,000 shares of Common Stock by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
June 24, 2024 Filed Jun 24, 2024 21:27 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	GiftCommon Stock	89,050	$0.00	$0.00	Disclosure SEC source: 0002007919-24-000024 · wk-form4_1719264429.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 1,061,360 F1 · kind: This transaction involved a gift of 89,050 shares of Common Stock by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to the reporting person's children, relatives, and other individuals. Of the shares gifted, 40,000 shares were gifted to the reporting person's adult children not residing in the reporting person's household, 22,825 shares were gifted to trusts for the benefit of individuals not residing in the reporting person's household, 4,150 shares were gifted to relatives not residing in the reporting person's household, and 2,075 shares were gifted to a UTMA for the benefit of a minor not residing in the reporting person's household, in each case to which the reporting person does not have a beneficial interest. F2 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
June 05, 2024 Filed Jun 7, 2024 22:05 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	PurchaseCommon Stock	8,265	$17.89	$147,860.85	Disclosure SEC source: 0002007919-24-000008 · wk-form4_1717797906.xml · nonDerivative · entry 2 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 1,150,410 F2 · price: The shares were purchased in multiple transactions at prices ranging from $17.81 to $18.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document
June 05, 2024 Filed Jun 7, 2024 22:05 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	PurchaseCommon Stock	49,284	$17.23	$849,163.32	Disclosure SEC source: 0002007919-24-000008 · wk-form4_1717797906.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 1,142,145 F1 · price: The shares were purchased in multiple transactions at prices ranging from $16.81 to $17.805, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document
June 04, 2024 Filed Jun 4, 2024 21:27 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	PurchaseCommon Stock	23,726	$18.24	$432,762.24	Disclosure SEC source: 0002007919-24-000006 · wk-form4_1717536444.xml · nonDerivative · entry 5 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 1,092,861 F5 · price: The shares were purchased in multiple transactions at prices ranging from $18.01 to $18.50, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document
June 04, 2024 Filed Jun 4, 2024 21:27 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	PurchaseCommon Stock	65,337	$17.44	$1,139,477.28	Disclosure SEC source: 0002007919-24-000006 · wk-form4_1717536444.xml · nonDerivative · entry 4 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 1,069,135 F4 · price: The shares were purchased in multiple transactions at prices ranging from $17.01 to $18.00, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document
June 03, 2024 Filed Jun 4, 2024 21:27 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	PurchaseCommon Stock	80,738	$17.90	$1,445,210.20	Disclosure SEC source: 0002007919-24-000006 · wk-form4_1717536444.xml · nonDerivative · entry 3 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 1,003,798 F3 · price: The shares were purchased in multiple transactions at prices ranging from $17.40 to $18.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document
June 03, 2024 Filed Jun 4, 2024 21:27 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	PurchaseCommon Stock	46,792	$16.61	$777,215.12	Disclosure SEC source: 0002007919-24-000006 · wk-form4_1717536444.xml · nonDerivative · entry 2 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 923,060 F2 · price: The shares were purchased in multiple transactions at prices ranging from $16.25 to $16.75, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document
May 31, 2024 Filed Jun 4, 2024 21:27 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	PurchaseCommon Stock	70,193	$16.14	$1,132,915.02	Disclosure SEC source: 0002007919-24-000006 · wk-form4_1717536444.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 876,268 F1 · price: The shares were purchased in multiple transactions at prices ranging from $15.75 to $16.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document
May 30, 2024 Filed May 30, 2024 22:22 UTC	Inhibrx, Inc. INBX · Entity 90351	Disposition to issuerStock Option (right to buy) · Derivative	15,000	Not disclosed Strike: $24.78	Not disclosed	Disclosure SEC source: 0000950142-24-001499 · es240484809_4-kayyem.xml · derivative · entry 7 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2031-06-07 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F8 · price: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock options immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F10 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on June 7, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document
May 30, 2024 Filed May 30, 2024 22:22 UTC	Inhibrx, Inc. INBX · Entity 90351	Disposition to issuerStock Option (right to buy) · Derivative	15,000	Not disclosed Strike: $12.57	Not disclosed	Disclosure SEC source: 0000950142-24-001499 · es240484809_4-kayyem.xml · derivative · entry 6 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2032-05-25 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F8 · price: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock options immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F9 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document
May 30, 2024 Filed May 30, 2024 22:22 UTC	Inhibrx, Inc. INBX · Entity 90351	Disposition to issuerStock Option (right to buy) · Derivative	15,000	Not disclosed Strike: $23.03	Not disclosed	Disclosure SEC source: 0000950142-24-001499 · es240484809_4-kayyem.xml · derivative · entry 5 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2033-05-25 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F8 · price: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock options immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F7 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document
May 30, 2024 Filed May 30, 2024 22:22 UTC	Inhibrx, Inc. INBX · Entity 90351	Disposition to issuerStock Option (right to buy) · Derivative	17,259	Not disclosed Strike: $10.52	Not disclosed	Disclosure SEC source: 0000950142-24-001499 · es240484809_4-kayyem.xml · derivative · entry 4 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,259 shares Expires 2028-11-26 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F8 · price: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock options immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F6 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on November 26, 2019, with the balance having vested and have become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document
May 30, 2024 Filed May 30, 2024 22:22 UTC	Inhibrx, Inc. INBX · Entity 90351	Disposition to issuerCommon Stock	25,000	$30.00	$750,000.00	Disclosure SEC source: 0000950142-24-001499 · es240484809_4-kayyem.xml · nonDerivative · entry 3 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Child B Disclosed balance after: 0 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2 · price: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company. F5 · ownership.nature: These securities were held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
May 30, 2024 Filed May 30, 2024 22:22 UTC	Inhibrx, Inc. INBX · Entity 90351	Disposition to issuerCommon Stock	25,000	$30.00	$750,000.00	Disclosure SEC source: 0000950142-24-001499 · es240484809_4-kayyem.xml · nonDerivative · entry 2 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Child A Disclosed balance after: 0 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2 · price: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company. F4 · ownership.nature: These securities were held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
May 30, 2024 Filed May 30, 2024 22:22 UTC	Inhibrx, Inc. INBX · Entity 90351	Disposition to issuerCommon Stock	3,224,301	$30.00	$96,729,030.00	Disclosure SEC source: 0000950142-24-001499 · es240484809_4-kayyem.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 0 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2 · price: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company. F3 · ownership.nature: These securities were directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
May 30, 2024 Filed May 30, 2024 22:10 UTC	Inhibrx Biosciences, Inc. INXB · Entity 4576	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $15.86	$0.00	Disclosure SEC source: 0000950142-24-001492 · es240484862_4-kayyem.xml · derivative · entry 4 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-30 F5 · date: This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi. F6 · derivative.exercise_date: This stock option will be fully exercisable on May 30, 2025, subject to the reporting person?s continued service through such date. Read SEC document
May 29, 2024 Filed May 30, 2024 22:10 UTC	Inhibrx Biosciences, Inc. INXB · Entity 4576	GrantCommon Stock	6,250	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-24-001492 · es240484862_4-kayyem.xml · nonDerivative · entry 3 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Child B Disclosed balance after: 6,250 F1 · price: The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9. F4 · ownership.nature: These securities are held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
May 29, 2024 Filed May 30, 2024 22:10 UTC	Inhibrx Biosciences, Inc. INXB · Entity 4576	GrantCommon Stock	6,250	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-24-001492 · es240484862_4-kayyem.xml · nonDerivative · entry 2 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Child A Disclosed balance after: 6,250 F1 · price: The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9. F3 · ownership.nature: These securities are held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
May 29, 2024 Filed May 30, 2024 22:10 UTC	Inhibrx Biosciences, Inc. INXB · Entity 4576	GrantCommon Stock	806,075	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-24-001492 · es240484862_4-kayyem.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 806,075 F1 · price: The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9. F2 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
May 21, 2024 Filed May 23, 2024 23:13 UTC	BIODESIX INC BDSX · Entity 6053	GrantStock Options (Right to Buy) · Derivative	37,050	$0.00 Strike: $1.57	$0.00	Disclosure SEC source: 0000905148-24-001609 · form4.xml · derivative · entry 2 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,050 Underlying: Common Stock · 37,050 shares Expires 2034-05-20 F4 · derivative.exercise_date: This option will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, this option will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. Read SEC document
May 21, 2024 Filed May 23, 2024 23:13 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	46,686	$0.00	$0.00	Disclosure SEC source: 0000905148-24-001609 · form4.xml · derivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,686 Underlying: Common Stock · 46,686 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. Read SEC document
January 01, 2024 Filed Jan 3, 2024 21:15 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	105,389	$0.00	$0.00	Disclosure SEC source: 0000905148-24-000040 · form4.xml · derivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,262 Underlying: Common Stock · 105,389 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. Read SEC document
August 03, 2023 Filed Aug 7, 2023 21:30 UTC	BIODESIX INC BDSX · Entity 6053	GrantCommon Stock	6,172	$1.62	$9,998.64	Disclosure SEC source: 0000905148-23-000622 · form4.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Jon Faiz Kayyem Revocable Trust Disclosed balance after: 180,085 F1 · ownership.nature: These securities are directly owned by The Jon Faiz Kayyem Revocable Trust, of which Jon Faiz Kayyem and his spouse serve as co-trustees. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
May 25, 2023 Filed May 30, 2023 20:07 UTC	Inhibrx, Inc. INBX · Entity 90351	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $23.03	$0.00	Disclosure SEC source: 0001739614-23-000050 · wk-form4_1685477228.xml · derivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-05-25 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on May 25, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document
May 23, 2023 Filed May 25, 2023 22:21 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	28,873	$0.00	$0.00	Disclosure SEC source: 0001140361-23-026718 · form4.xml · derivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,873 Underlying: Common Stock · 28,873 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2024, of an additional 105,389 RSUs that will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F4 · derivative.underlying_shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2024, of an additional 105,389 RSUs that will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. F4 · balance_after: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2024, of an additional 105,389 RSUs that will vest in full on March 31, 2024, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. Read SEC document
March 31, 2023 Filed Apr 4, 2023 20:36 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionRestricted Stock Units · Derivative	145,833	$0.00	$0.00	Disclosure SEC source: 0001140361-23-016261 · form4.xml · derivative · entry 3 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,878 Underlying: Common Stock · 145,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: These RSUs vested in full on March 31, 2023. F3 · derivative.expiration_date: These RSUs vested in full on March 31, 2023. F4 · balance_after: This amount includes 4,878 deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service to the Issuer. Read SEC document
March 31, 2023 Filed Apr 4, 2023 20:36 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	145,833	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-23-016261 · form4.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
January 23, 2023 Filed Jan 23, 2023 23:10 UTC	Inhibrx, Inc. INBX · Entity 90351	SaleCommon Stock	9,500	$25.26	$239,999.45	Disclosure SEC source: 0001739614-23-000008 · wf-form4_167451541190833.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 3,224,301 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. F2 · price: The shares were sold in multiple transactions at prices ranging from $25.00 to $25.61, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:31 UTC	BIODESIX INC BDSX · Entity 6053	GrantRestricted Stock Units · Derivative	4,878	$0.00	$0.00	Disclosure SEC source: 0001140361-23-000668 · form4.xml · derivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,711 Underlying: Common Stock · 4,878 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: This amount includes 4,878 deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service to the Issuer. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.